In addition, C16Cer was able to predict the risk of HCC with high diagnostic accuracy, even in AFP-negative patients (AUC = 0.766, OR = 1.030 (95% CI, 1.005–1.056)), highlighting a possible superior value of this biomarker compared with AFP [104]. The gene discussed is AFP; the disease is hepatocellular carcinoma.